Investments
95Portfolio Exits
53Partners & Customers
10Service Providers
1About Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) is a multi-national manufacturer of pharmaceutical, diagnostic, therapeutic, surgical, and biotechnology products, as well as personal hygiene products. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Want to inform investors similar to Johnson & Johnson about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Johnson & Johnson
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Johnson & Johnson in 9 Expert Collections, including Beauty & Personal Care.
Beauty & Personal Care
65 items
Startups in the beauty & personal care space, including cosmetics brands, shaving startups, on-demand beauty services, salon management platforms, and more.
Synthetic Biology
382 items
Fortune 500 Investor list
590 items
This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.
Conference Exhibitors
6,062 items
Companies that will be exhibiting at CES 2018
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Diabetes
1,904 items
Research containing Johnson & Johnson
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Johnson & Johnson in 9 CB Insights research briefs, most recently on Nov 30, 2022.
May 25, 2021 report
14 Trends Changing The Face Of The Beauty Industry In 2021
Aug 4, 2020
Here Are Q2’s Most Active Healthcare InvestorsLatest Johnson & Johnson News
Oct 18, 2022
Johnson & Johnson Posts Higher Quarterly Sales Despite Strong Dollar Healthcare-products firm trims full-year sales outlook after foreign-exchange reduced quarterly sales by 6% J&J posted a quarterly profit of $4.46 billion, or $1.68 a share, up from $3.67 billion, or $1.37 a share, a year earlier. FILE Photo: Mike Segar/REUTERS print (2 minutes) Johnson & Johnson posted higher sales for the recently ended quarter even as the stronger U.S. dollar dented results. The New Brunswick, N.J., healthcare-products company on Tuesday lowered its full-year sales guidance on the Continue reading your article with a WSJ membership Back to Top « Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved This copy is for your personal, non-commercial use only. Distribution and use of this material are governed byour Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contactDow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
Johnson & Johnson Investments
95 Investments
Johnson & Johnson has made 95 investments. Their latest investment was in OrthoSpin as part of their Series B on March 3, 2020.
Johnson & Johnson Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/31/2020 | Series B | OrthoSpin | $5M | Yes | 10 | |
11/14/2019 | Corporate Minority - IV | Founders Factory | Yes | 1 | ||
7/18/2018 | Corporate Minority | S-Biomedic | Yes | 3 | ||
2/2/2017 | Series A | |||||
12/17/2015 | Corporate Minority |
Date | 3/31/2020 | 11/14/2019 | 7/18/2018 | 2/2/2017 | 12/17/2015 |
|---|---|---|---|---|---|
Round | Series B | Corporate Minority - IV | Corporate Minority | Series A | Corporate Minority |
Company | OrthoSpin | Founders Factory | S-Biomedic | ||
Amount | $5M | ||||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 10 | 1 | 3 |
Johnson & Johnson Portfolio Exits
53 Portfolio Exits
Johnson & Johnson has 53 portfolio exits. Their latest portfolio exit was Kenvue on May 04, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
5/4/2023 | IPO | Kenvue | Public | 7 | |
5/3/2023 | Spinoff / Spinout | Kenvue | 2 | ||
12/16/2022 | Corporate Majority | 13 | |||
Date | 5/4/2023 | 5/3/2023 | 12/16/2022 | ||
|---|---|---|---|---|---|
Exit | IPO | Spinoff / Spinout | Corporate Majority | ||
Companies | Kenvue | Kenvue | |||
Valuation | |||||
Acquirer | Public | ||||
Sources | 7 | 2 | 13 |
Johnson & Johnson Acquisitions
61 Acquisitions
Johnson & Johnson acquired 61 companies. Their latest acquisition was Statewide Insurance on January 03, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
1/3/2023 | Acquired | 1 | ||||
12/22/2022 | Acq - P2P | 3 | ||||
6/7/2022 | Acquired Unit | 1 | ||||
8/19/2020 | Series C | |||||
12/20/2019 | Series B |
Date | 1/3/2023 | 12/22/2022 | 6/7/2022 | 8/19/2020 | 12/20/2019 |
|---|---|---|---|---|---|
Investment Stage | Series C | Series B | |||
Companies | |||||
Valuation | |||||
Total Funding | |||||
Note | Acquired | Acq - P2P | Acquired Unit | ||
Sources | 1 | 3 | 1 |
Johnson & Johnson Partners & Customers
10 Partners and customers
Johnson & Johnson has 10 strategic partners and customers. Johnson & Johnson recently partnered with Arrowhead Pharmaceuticals on February 2, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
2/7/2023 | Licensor | United States | Arrowhead confirms J&J’s plan to dial back hepatitis B drug research The apparent shift in strategy leaves the fate of Arrowhead Pharmaceuticals 's multibillion-dollar partnership with J&J unclear . | 1 | |
1/23/2023 | Partner | United States | CareSource, Walmart and Johnson & Johnson team up to improve health outcomes for Black mothers CareSource , Walmart and Johnson & Johnson team up to improve health outcomes for Black mothers . | 1 | |
9/26/2022 | Partner | Johnson & Johnson expands WiSTEM2D programme to MTU Johnson & Johnson has expanded its WiSTEM2D programme in partnership with Munster Technological University . | 1 | ||
8/9/2022 | Partner | ||||
6/27/2022 | Partner |
Date | 2/7/2023 | 1/23/2023 | 9/26/2022 | 8/9/2022 | 6/27/2022 |
|---|---|---|---|---|---|
Type | Licensor | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United States | United States | |||
News Snippet | Arrowhead confirms J&J’s plan to dial back hepatitis B drug research The apparent shift in strategy leaves the fate of Arrowhead Pharmaceuticals 's multibillion-dollar partnership with J&J unclear . | CareSource, Walmart and Johnson & Johnson team up to improve health outcomes for Black mothers CareSource , Walmart and Johnson & Johnson team up to improve health outcomes for Black mothers . | Johnson & Johnson expands WiSTEM2D programme to MTU Johnson & Johnson has expanded its WiSTEM2D programme in partnership with Munster Technological University . | ||
Sources | 1 | 1 | 1 |
Johnson & Johnson Service Providers
1 Service Provider
Johnson & Johnson has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Acq - P2P | Investment Bank | Financial Advisor |
Service Provider | |
|---|---|
Associated Rounds | Acq - P2P |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
Johnson & Johnson Team
159 Team Members
Johnson & Johnson has 159 team members, including current Executive Vice President, Vanessa Broadhurst.
Compare Johnson & Johnson to Competitors
AbbVie (NYSE: ABBV) researches and develops pharmaceutical products. The company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. It also offers treatments for diseases including multiple sclerosis, Parkinson's, and Alzheimer's disease. The company was founded in 2013 and is based in North Chicago, Illinois.
Fibroheal is a biotech and healthcare start-up company working exclusively on silk proteins as a biomaterial for wound healing focused on active and advanced wound care management. It offers tissue debridement, infection and inflammation control, moisture balance, re-epithelialization, scar management, post-operative wound care, active pharmaceutical ingredients, and more. The company was founded in 2017 and is based in Bengaluru, India.
Novo Nordisk is a global healthcare company that specializes in diabetes care. The company provides medical care for people with serious chronic diseases. It is based in Mainz, Germany.
Lilly is a pharmaceutical company. The company focuses on diabetes, cancer, immunology, pain, and neurodegeneration drugs. It is based in Toronto, Ontario.
Hale Therapeutics provides Hale, a connected vaporizer pen that lowers nicotine intake over time in a bid to curb smoking addiction. The company was founded in 2019 and is based in Philadelphia, Pennsylvania.
SYNAPS Dx focuses on the research, development, and commercialization of diagnostics for neurodegenerative disorders and conditions such as Alzheimer's Disease.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.